Without RCT, FDA May Consider Approval Of A Cross-Sex Hormone For Gender-Affirming Care

The FDA may consider approval of the cross-sex hormone estradiol for gender incongruence in adults and minors based on an observational study and not an RCT with placebo.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news